medigraphic.com
Colegio de Medicina Interna de México.

2011, Número 1

<< Anterior Siguiente >>

Med Int Mex 2011; 27 (1)


Disfunción no motora en la enfermedad de Parkinson: una enfermedad neurológica con manifestaciones multisistémicas

Cervantes-Arriaga A, Rodríguez-Violante M

Idioma: Español
Referencias bibliográficas: 56
Paginas: 29-37
Archivo PDF: 375.22 Kb.


RESUMEN

Antecedentes: la enfermedad de Parkinson es una trastorno neurodegenerativo caracterizado por: bradicinesia, temblor en reposo y rigidez: sin embargo, la enfermedad se acompaña de un amplio espectro de manifestaciones no motoras que, incluso, pueden precedera la fase motora.
Material y método: estudio retrospectivo efectuado con base en la bibliografía referente a síntomas no motores de pacientes con enfermedad de Parkinson que incluyeron: disfunción cognitiva, trastornos psiquiátricos, trastornos del sueño, disfunción autonómica y alteraciones sensoriales.
Resultados: los síntomas no motores de la enfermedad de Parkinson son de alta prevalencia, incluso en fases premotoras y con un efecto determinante en la calidad de vida de estos pacientes.
Conclusión: las características de la disfunción no motora las evalúan frecuentemente los médicos especialistas distintos a los neurólogos, por eso el reconocimiento de los síntomas como parte de la enfermedad de Parkinson es indispensable.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lim SY, Lang AE. The nonmotor symptoms of Parkinson’s disease – an overview. Mov Disord 2010; 25: S123-30.

  2. Pfeiffer RF. Parkinson disease. Nonmotor symptoms. In: Parkinson disease: The PRIAMO study. Nat Rev Neurol 2009; 5:531-532.

  3. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 2004; 52:784-788.

  4. Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson’s disease: non L-dopa-responsive problems dominate at 15 years. Mov Disord 2002;20:190-99

  5. Gulati A, Forbes A, Stegie F, Kelly L, Clough C, Chaudhauri KR. A clinical observational study of the pattern and ocurrence of non-motor symproms in Parkinson’s disease ranging from early to advanced disease. Mov Disord 2004;19(suppl9):S406

  6. O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: A clinicopathological study. Mov Disord 2007; 23: 101-06

  7. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010; 26:697-701.

  8. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197-210.

  9. Cummings JL. Depression and Parkisnon’s disease: a review. Am J Psychiatry 1992;149:443-454

  10. Starkstein SE, PreziosiTJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. J Nerv Ment Dis 1990;178:27-31

  11. Leentjens AFG, Lousberg R, Verhey FJR. Markers for depression in Parkisnon’s disease. Acta Pyschatr Scand 2002; 106:196-201

  12. Schrag A, Barone P, Brown G, Leentjens AFG, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson’s disease: Critique and recommendations. Mov Disord 2007;22:1077-92

  13. Levin BE, Katzen HL. Early cognitive changes and nondementing behavorial abnormalities in Parkisnon’s disease. Adv Neurol 1995;65:85-95

  14. Poewe W. Dysautonomia and cognitive dysfunction in Parkisnon’s disease. Mov Disord 2007;22(suppl 17):S374-8

  15. P. Martínez-Martín, B. Frades-Payo, C. Rodríguez-Blázquez, M.J. Forjaz, J. de Pedro-Cuesta, Grupo ELEP. Atributos psicométricos de la Scales for Outcomes in Parkinson’s Disease-Cognition (SCOPA-Cog), versión en castellano. Rev Neurol 2008; 47:337-43.

  16. Lauterbach EC, Duvoisin RC. Anxiety disorders in familial parkinsonism. Am J Psychiatry 1991:148:274

  17. Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress Anxiety 2000;11:185-6

  18. Fernadez HH, Friedman JH. Punding on L-Dopa. Mov Disord 1999; 14:836-8

  19. Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, et al. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15;23(4):484-500

  20. Wada-Isoe K, Ohta K, Imamura K, Kitayama M, Nomura T, et al. Assessment of hallucinations in Parkinson's disease using a novel scale. Acta Neurol Scand. 2008 Jan;117(1):35-40.

  21. Cummings JL. Behavorial complications of treatment of Parkisnon’s disease. J Am Geriatr Soc 1991; 33:708-16.

  22. Pfeiffer RF. Gastroinestinal, urological and sexual dysfunction in Parkinson’s disease. Mov Disord 2010; 25:S94-97.

  23. Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti K, et al. Dysautonomia rating scales in Parkinson’s disease: sialorrea, dysphagia and constipation – critique and recommendations by movement disorder task force on rating scales for Parkinson’s disease. Mov Disord 2009; 25:635-46.

  24. Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology 1989; 39:1309-1

  25. Leopold NA, Kagel MC. Pharyngo-esophageal dysphagia in Parkinson’s disease. Dysphagia 1997; 12:11-8

  26. Kanaoke Y, Koike Y, Sakurai N, et al. Gastrointestinal dysfunction in Parkinson’s disease detected by electrogastroenetrografía. J Auton Nerv Syst 1995;50:275-81

  27. Sakaibara R, Odaka T, Uchiyama, et al. Colonic transit time and rectoanal videomannometry in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:268-72.

  28. Abbot RD, Petrovich H, White LR. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001; 57: 456-62.

  29. Byrne KG, Pfieffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson’s disease: a report of clinical experience at a single center. J Clin Gastroenterol 1994;19:11-6.

  30. Mostile G, Jankovic J. Treatment of dysautonomia associated with Par’inson's disease. Parkinonism Relat Disord 2009;15:S224-32.

  31. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, et al. Practice parameter: treatment of nonmotor symtpoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:924-31.

  32. Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastroinestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord 1997; 12:952-7.

  33. Singer C, weiner WJ, Sanchez Ramos JR. Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol 1992;32:134-140

  34. Goldstein DS, Holmes C, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology 2002; 58:1247-55

  35. Satoh A, Serita T, Seto M, et al. Loss of [123I]MIBG uptake by the heart in Parkinson’s disease: assessment of cardiac sympathetic denervation diagnostic value. J Nucl Med 1999; 40:371-5

  36. Sage JI, Mark MH, Drenching sweats as an off phenomenon in Parkinson’s disease: treatment and relation to plasma levels of levodopa. Ann Neurol 1995;37:120-22

  37. Schestatsky P ,Ehlers J, Rieder C ,Gomes I. Evaluation of sympathetic skin response in Parkinson's disease. Park Rel Disord 2006; 12:486-91.

  38. Larsen JP. Sleep disorders in Parkinson’s disease. Adv Neurol 2003; 91:329-334

  39. Lai YY, Siegel JM. Physological and anatomical link between Parkinson-like disease and REM sleep behavior disorder. Mol Neurolbiol 2003; 27:137-152.

  40. Mondragón-Rezola E, Arratíbel-Echarren I, Ruiz-Martínez J, Martí-Massó JF. Trastornos del sueño en la enfermedad de Parkinson: insomnio y fragmentación del sueño, hipersomnia diurna, alteraciones del ritmo circadiano y síndrome de apnea del sueño. Rev Neurol 2010; 50 (Supl 2): S21-6.

  41. Ponsen MM, Stoffers D, Booi J, van Eck-Smit BL, Wolters ECh, Berendse HW. Idiopathic hypsomia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004; 56:173-81.

  42. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984; 32:489-502.

  43. Doty RL, Marcus A, Lee WW. Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT). Laryngoscope 1996; 106:353-356.

  44. Hummel T, Kobal G, Gudziol H, kay-Sim A. Normative data for the «Sniffin' Sticks» including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 2007; 264:237-243.

  45. Chaudhauri KR, Martínez-Marín P, Schapira AHV, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprenhensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Mov Disord 2007; 21:916-23

  46. Martínez-Marín P, Schapira AHV, Stocchi F, Sethi K, Odin P, MacPhee G, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting: Study using Nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007; 22:1623-29

  47. Chaudhauri KR, Martínez-Marín P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord 2007; 22:1901-11

  48. Propiedades métricas de instrumentos de disfunción no motora en enfermedad de Parkinson en población mexicana. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, López-Gómez M, Corona T. Rev Invest Clin. 2010; 62:8-14.

  49. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23:2129-70.

  50. Hobson P, Holden A, Meara J. Measuring the impact of Parkinson’s disease with the Parkinson’s disease quality of life questionnaire. Age Ageing 1999; 28:341-46

  51. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000; 69:308-12

  52. Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson’s disease. JNeurol Neurosurg Psychiatry 2003; 74:163-69

  53. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkisnon’s disease: frequent and disabling. Neurology 2002; 59:408-13

  54. Bjelland-Forsaa E, Petter-Larsen J, Wentzel-Larsen T, Herlofson K, Alves G. Predictors and course of healthrelated quality of life in Parkinson’s disease. Mov Disord 2008; Early View

  55. Marinus J, Ramaker C, van Hilten JJ, Stigellbout AM. Health related quality of life in Parkinson’s disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 2002; 72:241-48

  56. Parkinson J. An essay on the Shaking Palsy. En: Gowers W R, editor. A Manual of Diseases of the Nervous System. 2. Philadelphia, Blakiston; 1817. pp. 6366–6657.




2020     |     www.medigraphic.com